Moore M - Search Results

1

A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.

Tinker A, Winquist E, Canil C, Moore M, Murray RN, Chi KN. Tinker A, et al. Among authors: moore m. Am J Clin Oncol. 2006 Feb;29(1):3-7. doi: 10.1097/01.coc.0000200044.81711.57. Am J Clin Oncol. 2006. PMID: 16462494 Clinical Trial.

2

Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.

Bélanger K, Moore M, Baker SD, Dionne J, Maclean M, Jolivet J, Siu L, Soulières D, Wainman N, Seymour L. Bélanger K, et al. Among authors: moore m. J Clin Oncol. 2002 May 15;20(10):2567-74. doi: 10.1200/JCO.2002.12.047. J Clin Oncol. 2002. PMID: 12011137 Clinical Trial.

3

A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.

Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E. Tolcher AW, et al. Among authors: moore m. Clin Cancer Res. 2002 Aug;8(8):2530-5. Clin Cancer Res. 2002. PMID: 12171880 Clinical Trial.

4

The role of systemic chemotherapy in the management of muscle-invasive bladder cancer.

Juffs HG, Moore MJ, Tannock IF. Juffs HG, et al. Lancet Oncol. 2002 Dec;3(12):738-47. doi: 10.1016/s1470-2045(02)00930-0. Lancet Oncol. 2002. PMID: 12473515 Review.

5

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.

Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M. Stadler WM, et al. Among authors: moore m. Urol Oncol. 2002 Jul-Aug;7(4):153-7. doi: 10.1016/s1078-1439(02)00182-5. Urol Oncol. 2002. PMID: 12474531 Clinical Trial.

6

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.

Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Davis AJ, et al. Among authors: moore mj. Invest New Drugs. 2003 Feb;21(1):85-97. doi: 10.1023/a:1022976528441. Invest New Drugs. 2003. PMID: 12795533 Clinical Trial.

7

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.

Michael M, Brittain M, Nagai J, Feld R, Hedley D, Oza A, Siu L, Moore MJ. Michael M, et al. Among authors: moore mj. J Clin Oncol. 2004 Nov 1;22(21):4410-7. doi: 10.1200/JCO.2004.11.125. J Clin Oncol. 2004. PMID: 15514383 Clinical Trial.

8

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ. Knox JJ, et al. Among authors: moore mj. J Clin Oncol. 2005 Apr 1;23(10):2332-8. doi: 10.1200/JCO.2005.51.008. J Clin Oncol. 2005. PMID: 15800324 Clinical Trial.

9

Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.

Ernst DS, Brasher P, Venner PM, Czaykowski P, Moore MJ, Reyno L, Winquist E, Segal R, Hao D. Ernst DS, et al. Among authors: moore mj. Can J Urol. 2005 Apr;12(2):2575-80. Can J Urol. 2005. PMID: 15877938

10

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

Winquist E, Moore MJ, Chi KN, Ernst DS, Hirte H, North S, Powers J, Walsh W, Boucher T, Patton R, Seymour L. Winquist E, et al. Urol Oncol. 2005 May-Jun;23(3):143-9. doi: 10.1016/j.urolonc.2004.12.012. Urol Oncol. 2005. PMID: 15907712 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,476 results

Search Page

Filters